Company: TVRD
Filing Date: 2025-02-13
Form Type: CORRESP
Source: 0001104659-25-013055
Chunk: 3

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-13
Form: CORRESP
Chunk 3
---
 rights agreement, disclose the number of shares to be covered by the agreement, and clarify whether such     
 shares are also covered by the lock-up agreement.                                                                                         |

: The Company respectfully acknowledges the
Staff’s comment and has revised the disclosure on page 388 of the Second Amended Registration Statement to clarify which parties
will be subject to the registration rights agreement, to disclose the number of shares to be covered by the registration rights agreement
and to clarify that such shares are subject to the terms of the lock-up agreements.

MINTZ

| 7. | Please address the following regarding your response to prior comment 21, including your revisions 
 on pages 23-24:                                                                                    |

| · | You disclose on pages 23-24 that your assessment is based on “Cara’s discontinuation                                                   
 of its research and development activities, Asset Disposition, and settlement of its other remaining operating assets and liabilities, 
 immediately prior to Closing, Cara’s pre-combination assets are expected to primarily be cash, cash equivalents, and marketable        
 securities.” Revise to confirm the extent to which you believe that Cara will have no or nominal operations after the completion       
 of the events listed here.                                                                                                             |

| · | Please similarly revise your pro forma Note 4 on page 390. |

:
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 25 and 423 of the Second
Amended Registration Statement to clarify that following the discontinuation of its research and development activities, Asset Disposition,
and settlement of its other remaining operating assets and liabilities on the closing date the Company is expected to have nominal operations
and nominal pre-combination assets.

<div align='center'>*****</div>

| Sincerely,               |
| /s/ Daniel A. Bagliebter |
| Daniel A. Bagliebter     |

| Cc: | Jeffrey P. Schultz, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |

| Christopher                         
 Posner, Cara Therapeutics, Inc.     |
| Scott                               
 Terrillion, Cara Therapeutics, Inc. |
| Imran                               
 Alibhai, Tvardi Therapeutics, Inc.  |
| Rama                                
 Padmanabhan,  Esq., Cooley LLP      |